



REVENUES FOR THE SIX MONTHS TO JUNE 30, 2014

**Transformational first-half with
Total Group sales increasing by 42%**

Paris, France and Cambridge, UK – 24 July 2014 – Novacyt (ALTERNEXT: ALNOV), an international diagnostics manufacturer focused on cell-based diagnostics in the oncology and infectious disease markets, today announces its sales for the six months ended June 30, 2014 following the recent combination of Novacyt and Lab21 companies.

Revenue Highlights

42% increase in Group sales to €827.2k (H1 2013: €581.9k)*

- Sales from NovaPrep® in France increase 15% to €299.1k (H1 2013: €259.4k)
- Sales from NovaPrep® internationally decrease by 14% to €226.3k (H1 2013: €262.6k)
- Sales from NovaPrep® consumables increase 19% to €425.8k (H1 2013: €356.9k)
- Sales from NovaPrep® instrument sales decrease to €99.6k (H1 2013: €165.1k)
- Sales from Lab21 on a pro-forma basis increase 12% to €3.23m (H1 2013: €2.89m)

**the acquisition of Lab21 completed June 13, 2014 and the total Group sales include Lab21 for two weeks of June 2014*

Operational Highlights

- NovaPrep® has attracted increasing numbers of French pathologists, in both the public and private sectors and achieved over 1.2 Million cervical cancer screening Pap tests in France since launch
- France saw 5 new NovaPrep® site installations since January 2014 with total NovaPrep® consumable sales up 17%
- NovaPrep® instrument being used for Non Gyn Liquid Based Cytology with Pr. Hofman, Head of the Clinical & Experimental Pathology Laboratory of Nice University Hospital

Graham Mullis, Group CEO of Novacyt, commented:

“Following the completion of the Novacyt/Lab21 merger in June, we are focused on immediately integrating the two businesses and the management team have clear second half objectives which include the development of a new commercial strategy specifically for the NovaPrep® technology platform. We expect to announce the long-term commercial strategy once the interim results are available for the first half of 2014. In the meantime, the management team are focused on ensuring the Company will meet its financial and operational objectives for the full year.”



Chief Executive Statement

Novacyt is making good progress in integrating Lab21 into the business at management, commercial and operational levels. The new executive management team are focused on developing the long term strategy of the business to deliver strong sales growth and profitability.

The Company will focus its commercial strength on driving NovaPrep® sales growth which will be accelerated by the strength of distribution already established by Lab21's sales channel in emerging markets; particularly in the Middle-East, Asia and South America. Strong sales growth of the NovaPrep® platform is planned due to the demonstrable benefits and features of this technology which have been tested through 80 clinical laboratory and hospital installations since launch.

According to Dr. Cucherousset, President of the National College of Pathologists from General Hospitals in France who has been using NovaPrep® technology for a number of years and has recently commented, *"NovaPrep® technology is offering a high level of automation and diagnostic accuracy for PAP smears and offers hospitals and clinics an affordable screening tool."*

The Group, through Lab21 has an established sales base in over 100 countries and significant experience in other diagnostic markets including serology, haematology and microbiological infection disease markets. This commercial experience, strong brand reputation and market-leading niche products will underpin the future commercial plans and growth planned for NovaPrep®.

The first half sales for NovaPrep® in 2014 showed strong growth in France at 15% and the Company has identified the French market as being initially a key target market for the Company.

The international sales performance of NovaPrep® was disappointing in the first half of 2014 which is as a result of key Novacyt management focus on the Lab21 transaction. However, with the commercial management and international know-how of Lab21 there are new initiatives underway which should see international growth restored and accelerated.

Current trading and outlook

Novacyt has delivered a transformational transaction during H1 and at the same time delivered continued success in marketing the NovaPrep® platform into the French market. Lab21 during this period has also delivered solid revenue growth and is on track to meet the Board's full year FY14 expectations. The new management of Novacyt are focused on a rapid integration of the two businesses and finalising a new strategy for the Company with key performance indicators designed to deliver sales and profitability. This will be announced later this year.

- Ends -



About Novacyt Group

The Novacyt Group is a leader in the field of diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NovaPrep®, and a strong international network provided by Lab21, its UK diagnostics subsidiary, it is able to provide an extensive range of oncology and infectious disease products globally. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts:

For media and investor enquiries:

International Investor & Media

Tony Stephenson,

Exitus Communications,

+44 (0)7899 796655,

tony@exituscommunications.co.uk

French Investor & Media

Sophie Boulila / Emmanuel Huynh,

Newcap,

+33 (0)1 44 71 94 91,

novacyt@newcap.fr

NOVACYT

Graham Mullis

Chief Executive Officer

+44 7901 514121

Graham.mullis@lab21.com